Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors 1Neoplasms 1Lung Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Advanced Solid Tumors 1Acrocephalosyndactylia 1

Interventions

Carboplatin 5Paclitaxel 4pembrolizumab 3Educational Status 3niraparib 2anlotinib 2Therapeutic Touch 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy 2Pemetrexed 2Palliative Care 2Nivolumab 2Methods 2Interviews as Topic 2Gemcitabine 2Early Intervention, Educational 2Bevacizumab 2temsirolimus 1rucaparib 1relacorilant 1olaparib 1nintedanib 1nilotinib 1liposomal doxorubicin 1lenvatinib 1fosaprepitant 1atezolizumab 1argatroban 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × E-3810 × Clear all
NCT04042116 2022-12-20

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Clovis Oncology, Inc.

Phase 1/2 Suspended
227 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡